Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 9,196

Document Document Title
WO/2018/130625A1
The present invention relates to novel substituted benzene disulfonamides, as well as pharmaceutical compositions containing at least one of these substituted benzene disulfonamides together with at least one pharmaceutically acceptable ...  
WO/2018/130155A1
Compounds serving as histone deacetylase 6 (HDAC6) selective inhibitors, and applications thereof in the preparation of drugs for treating HDAC6-related diseases. Specifically disclosed are a compound as represented by formula (I) and a ...  
WO/2018/127194A1
Provided are a C-glycoside sodium-glucose transporter 2 inhibitor and a preparation method and use thereof. The inhibitor has a structure of general formula (I).  
WO/2018/124978A1
This present invention relates to a catalyst composition for a production process of δ-lactone from carbon dioxide and 1,3 -butadiene that can efficiently catalyze the synthesis reaction of δ-lactone with good selectivity of δ-lactone...  
WO/2018/124236A1
Provided is a medicinal composition to be used for treating an intractable heart tissue fibrosis disease accompanying chronic heart failure. The medicinal composition, which is to be used for treating an intractable heart tissue fibrosis...  
WO/2018/107180A1
The present technology is directed to polypropionate lactone stereotetrads of Formula (I) (or a pharmaceutically acceptable salt and/or solvate thereof) which are significant intermediates for multiple synthetic applications.  
WO/2018/104305A1
Substituted aromatic sulfonamides of formula (I) which are antagonists or negative allosteric modulators of P2X4, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a ph...  
WO/2018/105537A1
Provided is a compound which is different from conventional photo acid generators and is capable of generating a Lewis acid by means of light. According to the present invention, this compound is composed of an anionic component that has...  
WO/2018/100016A1
The present invention relates to 1-fluorocyclohexyl-methoxy-aryl compounds of formula (I), in which R1, R2, A1, A2, m and n are defined as indicated in claim 1, to their production, to their use as components in liquid crystal media and ...  
WO/2018/100834A1
Provided is a composition that has excellent near-infrared ray absorption stability and is useful for an optical film. The composition includes at least two of the compounds represented by general formula 2 or general formula 5.  
WO/2018/102419A1
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.  
WO/2018/089402A1
There are described RORγ Gamma modulators of the formula (I), (I) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutic...  
WO/2018/089449A1
The present invention is directed to benzocyclobutane derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity...  
WO/2018/086530A1
Provided is a series of sulfonamide compounds as a cccDNA inhibitor. Particularly, the present invention relates to a compound represented by formula (I) as a cccDNA inhibitor or a pharmaceutically acceptable salt thereof.  
WO/2018/087064A1
The invention relates to a method for producing triarylorganoborates from organoboronic acid esters in the presence of an n-valent cation 1/n Kn+, comprising the anhydrous treatment of the reaction mixture, and to the use of the obtained...  
WO/2018/083344A1
The present invention relates to a method for the cosmetic treatment of keratin materials, in particular the skin, comprising the application of a composition to the keratin materials, such as the skin, said composition comprising a comp...  
WO/2018/083341A1
The present invention relates to a method for the cosmetic treatment of keratin materials, comprising the application of a composition to the keratin materials, such as the skin, said composition comprising a compound (I), wherein R1, R2...  
WO/2018/079333A1
The present invention provides a spontaneous alignment assistant for liquid crystal compositions, which is capable of ensuring storage stability if added to a liquid crystal composition, while enabling vertical alignment of liquid crysta...  
WO/2018/066371A1
The purpose of the present invention is to provide a process for producing an E-olefin compound, the process being capable of using a wide range of Z-olefin compounds as substrates. The process, which is for producing an isomer, comprise...  
WO/2018/060354A1
The present invention relates to compounds of formula (I) and to pharmaceutical compositions containing them, wherein meanings of the substituents are indicated in the description. Such compounds for use in the treatment of cancer and ot...  
WO/2018/050631A1
The present invention relates to novel compounds of general formula (I) wherein the groups X, and R1 to R4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preven...  
WO/2018/041935A1
The present invention relates to photoinitiator compounds of the formula (1) wherein X is O, S or a direct bond; Y is O, S or CR9R10; R1, R2, R3, R4, R5, R6, R7 and R8 independently of each other are hydrogen, halogen, C1- C18alkyl, C5-C...  
WO/2018/034669A1
The present invention is directed to packaging films comprising an antioxidant based on 4-pyranone having a general structural formula: Formula (I).  
WO/2018/029264A1
Processes for the preparation of dapagliflozin reduce or eliminate impurities in dapagliflozin, preferably individual impurities are not more than 0.15% by HPLC.  
WO/2018/029611A1
The present invention generally relates to an improved process for the preparation of dapagliflozin of Formula I or its solvates or co-crystals thereof. The present invention also encompasses the novel intermediates and their use in the ...  
WO/2018/019549A1
The invention discloses 2-((2R,4R)-4-(4-(benzyloxy)-4-methylpent-2-yn-1-yl)-2-(tert- butyl)-5-oxo-1,3-dioxolan-4-yl)acetic acid of formula (XIX), a process for its preparation and processes for its conversion into enantiomerically pure (...  
WO/2018/014866A1
Disclosed are a crystal form of a dapagliflozin intermediate and a preparation method therefor, and specifically disclosed are a crystal form of the dapagliflozin intermediate (2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-2-eth ...  
WO/2017/221211A1
The present invention provides for crystalline Dapagliflozin butane –1,2– diol solvate (VIII), crystalline Dapagliflozin (S) butane –1,2– diol solvate (VIIIa) and Dapagliflozin (R) butane –1,2– diol solvate (VIIIb). The prese...  
WO/2017/219510A1
A quinoid chalcone c-glycoside dimer compound having an anti-tumor activity and an anti-inflammatory activity and a method for preparing same. The compound is a quinoid chalcone c-glycoside dimer compound separated from Carthamus tinctor...  
WO/2017/216791A9
Provided herein is a conjugate comprising two residues of structurally and/or mechanistically different anticancer bioactive agents, coupled to one another by a biocleavable linking moiety, as well as methods of treating cancer using the...  
WO/2017/216791A1
Provided herein is a conjugate comprising two residues of structurally and/or mechanistically different anticancer bioactive agents, coupled to one another by a biocleavable linking moiety, as well as methods of treating cancer using the...  
WO/2017/206808A1
Provided is a process for preparing a dapagliflozin eutectic, comprising: 1) using a 4-chloro-3-(4-ethoxybenzyl)phenyl halide 6 as a raw material, reacting 6 with lithium alkylide and a zinc salt via an X/Li/Zn exchange reaction in an ap...  
WO/2017/206827A1
Disclosed are a crystal form of an L-proline cocrystal of a sodium-glucose cotransporter 2 inhibitor, a preparation method therefor, and a pharmaceutical composition and a use therof. Particularly involved are the crystal form of the L-p...  
WO/2017/207539A1
The invention relates to tetrahydropyranyl lower alkyl esters and particularly tetrahydropyranyl acetates, a method for producing same using ketene, and the use of same as fragrant and aromatic substances.  
WO/2017/202365A1
Provided are a preparation method for a trifluoromethyl-substituted pyran derivative and an intermediate thereof, namely, a preparation method for a compound as shown in formula (I) and an intermediate thereof. The method is characterize...  
WO/2017/202644A1
The present invention relates to methods of forming delta-lactone compounds by reaction of a diene with carbon dioxide in the presence of Pd and a phosphine ligand.  
WO/2017/202264A1
Disclosed are a new dapagliflozin crystal form and a preparation method and use thereof. In particular, disclosed are a crystal form E of 2-chloro-5-(β-D-glucopyranose-1-yl)-4'-ethyoxyldiphenylmeth ane and a preparation method therefor,...  
WO/2017/202357A1
Provided is a method for preparing a trifluoromethyl-substituted pyran derivative, that is, a method for preparing the compound shown in formula (I) and an intermediate thereof. The method has the advantages of having mild reaction condi...  
WO/2017/201407A1
A hydrogel particle comprising: cross-linked dextran aldehyde (oxidized dextran), comprising the redox sensitive disulfide cross-linker cystamine (2,2'-disulfanediyldiethanamine), the anti-tumor agent doxorubicin conjugated to the cross-...  
WO/2017/198202A1
Disclosed are a novel polycrystalline form of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-me thyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2 -indolinone (nintedanib), a manufacturing method thereof, and a pharm...  
WO/2017/192304A1
The present disclosure is directed to compounds of formula (I): or a pharmaceutically acceptable salt, solvate or solvate of the salt thereof. Compounds of formula (I) are inhibitors of NOX4 and are useful in the treatment of fibrotic di...  
WO/2017/187859A1
The present invention is a compound represented by formula (1), a liquid crystal composition containing the compound, and a liquid crystal display element including the composition. In the formula: R is a C1-15 alkyl or the like; ring A1...  
WO/2017/184984A1
Molecular characterization of disease has become the dominant trend in modern medicine, and it has recently become increasingly important to obtain qPCR, microarray, and next-generation sequencing (NGS) data for both research and clinica...  
WO/2017/183723A1
The present invention addresses the problem of providing a novel compound having a strong opening action with respect to KCNQ 2-5 channels. Provided is a compound represented by the general formula (I) (in the formula, the definitions of...  
WO/2017/183581A1
Provided are a composition and the like having Tie2 activation effect, vascular permeability suppression effect, vascular maturation effect, vascular normalization effect, vascular stabilization effect, lymph vessel stabilization effect,...  
WO/2017/174827A1
The invention relates primarily to the use of one or more stereoisomers of compounds of formula (I) for modifying and/or intensifying the odour sensation of one or more aromas with a lily of the valley scent. The invention also relates t...  
WO/2017/167969A1
Methods for producing ferric maltol compositions, such as ferric trimaltol, from elemental iron, andferric maltol compositions produced by these methods and their usesare described.  
WO/2017/167963A1
Methods for producing ferric maltol compositions, such as ferric trimaltol,are described in which maltolis reacted with a ligand modified ferric hydroxide and/or a ligand coated ferric hydroxide.  
WO/2017/170859A1
The purpose of the present invention is to provide a compound that inhibits the collagen binding function of an HSP47 essential for the extracellular secretion of collagen. The present invention provides a bisaryl derivative indicated by...  
WO/2017/167970A1
Methods for producing ferric maltol compositions, such as ferric trimaltol, from ferrous hydroxides, are described, as well as ferric maltol compositions produced by these methods and their uses.  

Matches 1 - 50 out of 9,196